REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:RGNX
- CUSIP: N/A
- Web: www.regenxbio.com
Capitalization:- Market Cap: $588.68 million
- Outstanding Shares: 30,821,000
Average Prices:- 50 Day Moving Avg: $19.78
- 200 Day Moving Avg: $19.37
- 52 Week Range: $7.52 - $24.55
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.70
- P/E Growth: 0.29
Sales & Book Value:- Annual Revenue: $4.65 million
- Price / Sales: 126.60
- Book Value: $7.04 per share
- Price / Book: 2.71
Profitability:- EBIDTA: ($75,960,000.00)
- Net Margins: -1,595.18%
- Return on Equity: -39.52%
- Return on Assets: -37.15%
Debt:- Current Ratio: 14.95%
- Quick Ratio: 14.95%
Misc:- Average Volume: 241,790 shs.
- Beta: -0.69
- Short Ratio: 6.25
Frequently Asked Questions for REGENXBIO (NASDAQ:RGNX)
What is REGENXBIO's stock symbol?
REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."
How were REGENXBIO's earnings last quarter?
REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday, May, 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.06. The firm earned $0.46 million during the quarter. REGENXBIO had a negative net margin of 1,595.18% and a negative return on equity of 39.52%. View REGENXBIO's Earnings History.
Where is REGENXBIO's stock going? Where will REGENXBIO's stock price be in 2017?
2 brokerages have issued twelve-month price objectives for REGENXBIO's stock. Their predictions range from $25.00 to $50.00. On average, they anticipate REGENXBIO's share price to reach $37.50 in the next twelve months. View Analyst Ratings for REGENXBIO.
Who are some of REGENXBIO's key competitors?
Some companies that are related to REGENXBIO include Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Xencor (XNCR), Insmed (INSM), Acorda Therapeutics (ACOR), Omeros Corporation (OMER), Aduro Biotech (ADRO), Synergy Pharmaceuticals (SGYP), NeuroDerm (NDRM), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), ZIOPHARM Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO), Epizyme (EPZM), Aclaris Therapeutics (ACRS), Flexion Therapeutics (FLXN) and Retrophin (RTRX).
Who are REGENXBIO's key executives?
REGENXBIO's management team includes the folowing people:
- Donald J. Hayden Jr., Independent Chairman of the Board
- Kenneth T. Mills, President, Chief Executive Officer, Executive Director
- Vittal K. Vasista, Chief Financial Officer
- Patrick J. Christmas, Senior Vice President, General Counsel
- Curran M. Simpson, Senior Vice President - Technical Operations
- Olivier Danos Ph.D., Chief Scientific Officer
- Faraz Ali, Chief Business Officer
- Stephen Yoo M.D., Chief Medical Officer
- Allan M. Fox, Director
- Daniel J. Abdun-Nabi, Independent Director
How do I buy REGENXBIO stock?
Shares of REGENXBIO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is REGENXBIO's stock price today?
One share of REGENXBIO stock can currently be purchased for approximately $19.10.
MarketBeat Community Rating for REGENXBIO (NASDAQ RGNX)MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for REGENXBIO (NASDAQ:RGNX)Earnings History by Quarter for REGENXBIO (NASDAQ RGNX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.76) | ($0.82) | | $0.46 million | View | Listen |  |
| 3/7/2017 | Y 2016 | ($0.75) | ($0.74) | | $1.70 million | View | Listen | |
| 5/5/2016 | | ($0.40) | ($0.41) | | $0.39 million | View | N/A | |
| 3/3/2016 | Q415 | ($0.34) | ($0.20) | $1.23 million | $4.40 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.35) | ($1.52) | | $1.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for REGENXBIO (NASDAQ:RGNX)Current Year EPS Consensus Estimate: $-3.12 EPS
Next Year EPS Consensus Estimate: $-3.35 EPS
Dividend History for REGENXBIO (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for REGENXBIO (NASDAQ:RGNX)Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 67.33%
Insider Trades by Quarter for REGENXBIO (NASDAQ:RGNX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/17/2017 | Vittal Vasista | CFO | Sell | 3,100 | $19.81 | $61,411.00 | |
| 6/20/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $19.68 | $127,920.00 | |
| 6/15/2017 | Vittal Vasista | CFO | Sell | 3,100 | $18.75 | $58,125.00 | |
| 4/24/2017 | Donald J Hayden Jr | Director | Sell | 10,000 | $20.98 | $209,800.00 | |
| 4/24/2017 | Kenneth T Mills | Insider | Sell | 15,440 | $20.98 | $323,931.20 | |
| 4/24/2017 | Vittal Vasista | CFO | Sell | 3,100 | $21.00 | $65,100.00 | |
| 5/17/2016 | Fmr Llc | Insider | Sell | 18,300 | $12.41 | $227,103.00 | |
| 5/16/2016 | Fmr Llc | Insider | Sell | 16,030 | $11.65 | $186,749.50 | |
| 5/12/2016 | Fmr Llc | Insider | Sell | 6,711 | $10.85 | $72,814.35 | |
| 5/11/2016 | Fmr Llc | Insider | Sell | 25,132 | $10.36 | $260,367.52 | |
| 5/9/2016 | Fmr Llc | Insider | Sell | 10,570 | $9.94 | $105,065.80 | |
| 5/4/2016 | Fmr Llc | Insider | Sell | 1,896 | $10.51 | $19,926.96 | |
| 5/3/2016 | Fmr Llc | Insider | Sell | 6,046 | $10.76 | $65,054.96 | |
| 4/29/2016 | Fmr Llc | Insider | Sell | 4,723 | $10.80 | $51,008.40 | |
| 4/28/2016 | Fmr Llc | Insider | Sell | 33,196 | $11.23 | $372,791.08 | |
| 4/26/2016 | Fmr Llc | Insider | Sell | 9,188 | $11.19 | $102,813.72 | |
| 4/22/2016 | Fmr Llc | Insider | Sell | 20,558 | $11.30 | $232,305.40 | |
| 4/20/2016 | Fmr Llc | Insider | Sell | 13,189 | $11.66 | $153,783.74 | |
| 4/18/2016 | Fmr Llc | Insider | Sell | 18,900 | $11.75 | $222,075.00 | |
| 4/14/2016 | Fmr Llc | Insider | Sell | 27,036 | $11.46 | $309,832.56 | |
| 9/22/2015 | James E Flynn | Insider | Buy | 175,000 | $22.00 | $3,850,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for REGENXBIO (NASDAQ:RGNX)
Latest Headlines for REGENXBIO (NASDAQ:RGNX)
| Source: |
|
| Date | Headline |
|---|
 | REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : July 19, 2017
finance.yahoo.com - July 20 at 7:11 AM |
 | REGENXBIO Inc. (RGNX) CFO Sells $61,411.00 in Stock
www.americanbankingnews.com - July 19 at 8:00 PM |
| -$0.81 Earnings Per Share Expected for REGENXBIO Inc. (RGNX) This Quarter
www.americanbankingnews.com - July 17 at 10:57 AM |
| REGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium
finance.yahoo.com - July 7 at 8:22 AM |
| Insider Selling: REGENXBIO Inc. (RGNX) Insider Sells 6,500 Shares of Stock
www.americanbankingnews.com - June 22 at 7:48 PM |
| REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 21, 2017
finance.yahoo.com - June 22 at 10:44 AM |
| Brokerages Set $37.00 Target Price for REGENXBIO Inc. (RGNX)
www.americanbankingnews.com - June 21 at 6:32 PM |
| REGENXBIO Inc. (RGNX) Expected to Announce Earnings of -$0.81 Per Share
www.americanbankingnews.com - June 21 at 7:34 AM |
| REGENXBIO Inc. (RGNX) CFO Sells $58,125.00 in Stock
www.americanbankingnews.com - June 19 at 7:56 PM |
| ETFs with exposure to REGENXBIO, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 9:21 AM |
| Short Interest in Regenxbio Inc (RGNX) Expands By 4.6%
www.americanbankingnews.com - June 10 at 7:22 AM |
| REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 8, 2017
finance.yahoo.com - June 8 at 8:38 AM |
 | AveXis (AVXS), REGENXBIO (RGNX) Announce New Licenses for Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
www.streetinsider.com - June 7 at 7:32 PM |
| AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
finance.yahoo.com - June 7 at 7:32 PM |
| REGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
finance.yahoo.com - June 7 at 7:32 PM |
| ETFs with exposure to REGENXBIO, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 8:15 PM |
| REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 10:47 PM |
| REGENXBIO Announces Initiation of Phase I Clinical Trial of RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
finance.yahoo.com - May 31 at 12:50 PM |
| Brokerages Anticipate Regenxbio Inc (RGNX) to Announce -$0.80 EPS
www.americanbankingnews.com - May 26 at 12:30 AM |
| REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 24 at 7:55 PM |
| Regenxbio Inc (RGNX) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - May 12 at 10:41 PM |
| REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 10 at 7:44 PM |
| Regenxbio Inc (RGNX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 6:58 PM |
| Edited Transcript of RGNX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:13 AM |
| Investor Network: REGENXBIO, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 7:04 PM |
| REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 9 at 7:04 PM |
 | Regenxbio reports 1Q loss
marketbeat.com - May 9 at 6:45 PM |
| REGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : May 5, 2017
finance.yahoo.com - May 5 at 7:47 PM |
| REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : May 4, 2017
finance.yahoo.com - May 4 at 7:45 PM |
| Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences
finance.yahoo.com - May 4 at 7:45 PM |
| Regenxbio (RGNX) Getting Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - May 3 at 2:56 PM |
| -$0.76 Earnings Per Share Expected for Regenxbio Inc (RGNX) This Quarter
www.americanbankingnews.com - May 2 at 8:02 PM |
| REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 2 at 5:21 PM |
| Regenxbio (RGNX) Earns Media Impact Rating of 0.25
www.americanbankingnews.com - April 30 at 10:36 AM |
| Regenxbio (RGNX) Getting Somewhat Negative Press Coverage, Study Shows
www.americanbankingnews.com - April 27 at 6:48 PM |
| Vittal Vasista Sells 3,100 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - April 26 at 11:38 PM |
| Insider Selling: Regenxbio Inc (RGNX) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - April 26 at 11:32 PM |
| Regenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 15,440 Shares
www.americanbankingnews.com - April 26 at 11:30 PM |
| REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 26 at 5:46 PM |
| Regenxbio (RGNX) Receiving Very Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 18 at 9:24 AM |
| Chardan Capital Increases Regenxbio Inc (RGNX) Price Target to $50.00
www.americanbankingnews.com - April 17 at 7:56 AM |
| Regenxbio (RGNX) Given Daily News Impact Score of -0.04
www.americanbankingnews.com - April 15 at 2:13 PM |
| Regenxbio Inc (RGNX) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 15 at 7:12 AM |
| Regenxbio Inc (RGNX) Expected to Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 13 at 12:14 PM |
| Regenxbio Inc (RGNX) Lowered to "D+" at TheStreet
www.americanbankingnews.com - April 11 at 2:45 PM |
| Zacks: Analysts Expect Regenxbio Inc (RGNX) Will Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - April 11 at 2:13 PM |
| Regenxbio Inc. (RGNX) PT Raised to $50 at Chardan Capital Markets on News Dr. Olivier Danos is New CSO; 'Watershed Moment'
www.streetinsider.com - April 11 at 10:02 AM |
| REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017
finance.yahoo.com - April 7 at 12:14 PM |
| Regenxbio Inc (RGNX) Given $30.25 Consensus Target Price by Analysts
www.americanbankingnews.com - April 6 at 8:04 AM |
| Regenxbio Inc (RGNX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:29 AM |
REGENXBIO (RGNX) Chart for Friday, July, 21, 2017
